On January 10, 2024, EyePoint Pharmaceuticals, Inc. released an updated investor presentation and announced the dosing of the first patient in phase 2 of the EYP-1901 clinical trial for diabetic macular edema (DME). The presentation, which includes financial information as of December 31, 2023, was filed with the SEC and is available on the company's website. The phase 2 trial is part of the company's ongoing efforts to develop EYP-1901, a potential treatment for serious eye diseases including wet age-related macular degeneration and non-proliferative diabetic retinopathy. The company's strong financial position was highlighted, with over $330 million in cash and investments as of the end of 2023, bolstered by a $230 million equity financing completed on December 5, 2023. This financial stability is expected to support...Show More

On January 10, 2024, EyePoint Pharmaceuticals, Inc. released an updated investor presentation and announced the dosing of the first patient in phase 2 of the EYP-1901 clinical trial for diabetic macular edema (DME). The presentation, which includes financial information as of December 31, 2023, was filed with the SEC and is available on the company's website. The phase 2 trial is part of the company's ongoing efforts to develop EYP-1901, a potential treatment for serious eye diseases including wet age-related macular degeneration and non-proliferative diabetic retinopathy. The company's strong financial position was highlighted, with over $330 million in cash and investments as of the end of 2023, bolstered by a $230 million equity financing completed on December 5, 2023. This financial stability is expected to support the company through topline data for Phase 3 wet AMD pivotal trials. The investor presentation also detailed the promising results of the DAVIO 2 clinical trial, which met all primary and secondary endpoints, suggesting EYP-1901's potential as a maintenance treatment for wet AMD with a favorable safety profile and a significant reduction in treatment burden.